Promoted Content Promoted Content

X

Find Clinical Drug Pipeline Developments & Deals by Lonza Group

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Therapeutic Area filter
    Study Phase filter
      Country filter
        News Type filter
          Company filter
            refresh

            Companies By Therapeutic Area Full Screen

            Development Status Full Screen

            Virtual BoothGlobal Pharmaceutical Dosage Solutions Company

            Contact the Supplier

            Lead Product(s): ATYR2810

            Therapeutic Area: Oncology Product Name: ATYR2810

            Highest Development Status: IND Enabling Product Type: Large molecule

            Partner/Sponsor/Collaborator: aTyr Pharma

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership April 14, 2021

            Details:

            Under the terms of the agreement, Lonza will utilize its Ibex® Design, a fully integrated end-to-end program, to manufacture cGMP material for ATYR2810.

            Virtual BoothGlobal Pharmaceutical Dosage Solutions Company

            Contact the Supplier

            Lead Product(s): Ixovex-1

            Therapeutic Area: Oncology Product Name: Ixovex-1

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: PsiVac

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement March 08, 2021

            Details:

            Under the terms of the parties’ strategic agreement, PsiVac will grant Lonza the exclusive right to cGMP manufacture the Ixovex-1 product.

            Virtual BoothGlobal Pharmaceutical Dosage Solutions Company

            Contact the Supplier

            Lead Product(s): ARU-1801

            Therapeutic Area: Genetic Disease Product Name: ARU-1801

            Highest Development Status: Phase I/ Phase II Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Aruvant Sciences

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership January 18, 2021

            Details:

            The agreement aims to support ARU-1801, Aruvant’s one-time investigational gene therapy for sickle cell disease (SCD). Aruvant has chosen Lonza to help develop and manufacture ARU-1801 for its upcoming pivotal trial.

            Virtual BoothGlobal Pharmaceutical Dosage Solutions Company

            Contact the Supplier

            Lead Product(s): Allogeneic cardiosphere-derived cells

            Therapeutic Area: Genetic Disease Product Name: CAP-1002

            Highest Development Status: Phase II Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Capricor Therapeutics

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration January 12, 2021

            Details:

            Capricor to leverage Lonza’s expertise in technology transfer and development of cellular therapies to take CAP-1002 through potential product launch and commercial supply.